Antisense oligonucleotides: Promise and reality

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 403-419

  Lebedeva, I ^a   Stein, C A ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Bcl 2; Gene expression; Inhibition; Phosphorothioates; RNase H

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NUCLEASE; OLIGONUCLEOTIDE; PHOSPHODIESTER OLIGONUCLEOTIDE DERIVATIVE; PHOSPHOROTHIOATE OLIGONUCLEOTIDE DERIVATIVE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ANIMALS; DOWN-REGULATION; GENE EXPRESSION; GENES, BCL-2; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0035028575     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.403     Document Type: Review

References (89)

1. Antisense inhibition of gene expression
2. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma
3. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides
4. Antisense oligonucleotide methylphosphonates
5. A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression)
6. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes
7. Morpholino antisense oligomers: Design, preparation, and properties
8. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)
9. Patterns of intracellular compartmentalization, trafticking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells
10. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides
11. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: Diastereoselectivity of plasma 3′-exonuclease
12. Nucleoside phosphorothioates
13. Physicochemical properties of phosphorothioate oligodeoxynucleotides
14. Antitumor activity of a PKCalpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice
15. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
16. First- and secondgeneration antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies
17. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development
18. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
19. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
20. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
21. Antisense therapy of hematologic malignancies
22. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
23. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment
24. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
25. Bcl-xL-directed oligonucleotides in prostate and bladder carcinoma cell lines
26. Two problems in antisense biotechnology: In vitro delivery and the design of antisense experiments
27. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
28. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides
29. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides
30. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides
31. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein
32. Oligodeoxynucleotides interact with recombinant CD4 at multiple sites
33. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120
34. Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide
35. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells
36. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology
37. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides
38. Selection of singlestranded DNA molecules that bind and inhibit human thrombin
39. Biological activity of guanosine quartet-forming oligonucleotides
40. Solution structure of a parallel-stranded G-quadruplex DNA
41. G-quartet inhibitory effects of phosphorothioate oligonucleotides
42. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro
43. Temperature and salt dependence of higher order structure formation by antisense c-myc and c-myb phosphorothioate oligodeoxyribonucleotides containing tetraguanylate tracts
44. Determining the influence of structure on hybridization using oligonucleotide arrays
45. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability
46. Use of cationic lipid complexes for antisense oligonucleotide delivery
47. Tetranucleotide GGGA motif in primary RNA transcripts: Novel target site for antisense design
48. Bias in nucleotide composition of antisense oligonucleotides
49. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
50. The use of singlestranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
51. Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents
52. Antisense oligonucleotide-directed cleavage of mRNA in Xenopus oocytes and eggs
53. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells
54. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds
55. Evaluation of 2′ -modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
56. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures
57. Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides
58. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression
59. Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
60. Translationally associated helixdestabilizing activity in rabbit reticulocyte lysate
61. Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome
62. RNA enzyme-directed gene therapy
63. External guide sequences for an RNA enzyme
64. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences
65. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
66. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells
67. Synthesisof Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines
68. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C
69. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs
70. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
71. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
72. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
73. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
74. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
75. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
76. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
77. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
78. In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue
79. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
80. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
81. Bcl-2-antisense therapy in lymphoma: In vitro and in vivo mechanisms, efficacy, pharmacokinetics and toxicity studies
82. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
83. Human Bcl-2 antisense therapy for lymphomas
84. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
85. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
86. A phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma
87. A phase I study of BCL-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
88. A phase I/IIA dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies